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Abstract
A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-
wide effect on HIV control in European Americans and is also associated with the level of HLA-C
expression. We characterized the differential cell surface expression levels of all common HLA-C
allotypes and tested directly for effects of HLA-C expression on outcomes of HIV infection in
5243 individuals. Increasing HLA-C expression was associated with protection against multiple
outcomes independently of individual HLA allelic effects in both African and European
Americans, regardless of their distinct HLA-C frequencies and linkage relationships with HLA-B
and HLA-A. Higher HLA-C expression was correlated with increased likelihood of cytotoxic T
lymphocyte responses and frequency of viral escape mutation. In contrast, high HLA-C expression
had a deleterious effect in Crohn’s disease, suggesting a broader influence of HLA expression
levels in human disease.
Variation within the human leukocyte antigen (HLA) class I genes of the major
histocompatibility complex (MHC) has the greatest impact on outcome after HIV infection
relative to the rest of the genome (1–3). A single-nucleotide polymorphism 35 kb upstream
of the HLA-C locus (rs9264942) showed the most significant association with viral load
(VL) control in a recent genome-wide association study (GWAS) (2) and the second most
significant association in an earlier HIV GWAS where VL at set point was considered (3).
We previously reported that rs9264942 genotype correlated with the level of HLA-C cell
surface protein expression on primary T cells from European Americans (4). Whether
rs9264942 is associated with the outcome of HIV infection because it marks HLA-C
expression levels or individual HLA alleles that affect HIV remains unknown (4, 5).
If HLA-C expression levels have a direct influence on HIV control, then we expect to
observe the effect across ethnic groups, despite their distinct HLA-C allele frequencies and
linkage disequilibrium (LD) relationships with HLA-A and -B alleles (6). Unlike in
European Americans, rs9264942 is in poor LD with HLA-C alleles in African Americans
and does not mark expression levels of HLA-C or associate with HIV control in large
studies (2, 7) (fig. S1). We determined the expression levels of individual HLA-C allotypes
in African Americans, which showed a continuous distribution (Fig. 1), in order to test an
effect of HLA-C expression level on HIV control.
HLA-C alleles that are present in both African and European Americans show the same
relative expression levels in the two populations (4) (Fig. 1). Indeed, a highly significant
correlation was observed in both 50 European-American and 50 African-American donors
when comparing the observed HLA-C expression levels with expected levels based on mean
expression of each HLA-C allele observed in an independent group of 150 African
Americans (fig. S2). After confirming that HIV infection does not alter HLA-C expression
(fig. S2), we used the mean expression of individual HLA-C alleles measured in all 200
African-American donors to assign HLA-C expression levels to each HIV-infected subject
based on their HLA-C genotypes (8). An effect of HLA-C expression level was tested, along
with all individual HLA class I alleles, in chronically infected subjects using logistic
regression with stepwise selection. HLA-C expression level showed a significant
independent association with HIV control in an analysis of 2527 European-American
patients [P = 1 × 10−7, odds ratio (OR) = 0.52] (Table 1), where OR for HLA-C expression
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represents the protection conferred by a difference of 100 higher median fluorescence
intensity (MFI) expression units (Fig. 1). The average difference in expression of 224 units
between Cw*07 and Cw*06 homozygotes, for example, would correspond to an OR of 0.24.
The protective effect of high HLA-C expression level in European Americans was mirrored
in an analysis of 1209 African-American patients, where expression had the third most
significant independent effect (P = 8 × 10−6, OR = 0.61) (Table 1) after HLA-B*57:03 and
B*81, two well-documented protective alleles in cohorts of African descent (7, 9). Similar
results were observed when mean VL was considered as a continuous variable (table S1).
Although our African-American population is admixed to some extent with European
genotypes, it is clearly distinct from our European-American cohorts (fig. S1). The effect of
HLA-C expression level persisted when increasing the stringency at which covariates were
considered to have independent effects, and permutation analyses indicated that the
distribution of HLA-C allelic expression values observed are unlikely to correlate with HIV
control by chance (8).
HLA-C expression level showed the most significant effect on progression from
seroconversion to CD4 < 200 in a cohort of 1069 subjects [P = 1 × 10−6, hazard ratio (HR) =
0.67 for a difference of 100 MFI expression units] relative to all individual HLA alleles
(Table 2). Thus, the continuous distribution of HLA-C allele expression levels correlates
with multiple outcomes of HIV infection, tested in three distinct cohorts: longitudinal VL in
European Americans, longitudinal VL in African Americans, and progression to CD4 < 200
in a separate cohort of European and African Americans combined (8). Use of regression
models that include all HLA class I alleles as covariates, along with consistent effects across
African and European Americans, strongly point to HLA-C expression level as a major
independent contributor to control of HIV.
A direct genetic effect of HLA-C expression level on HIV control predicts that more highly
expressed HLA-C allotypes would confer greater immune pressure on the virus, which can
be assessed by measuring the strength of association between a given HLA-C allele and
corresponding mutations in the viral genome. HLA class I genotypes and nearly full-length
HIV sequences were generated in a cohort of 1888 clade B chronically infected patients (the
majority Caucasian) who were treatment naïve. A phylogenetically corrected logistic
regression approach was used to estimate the probability of postinfection escape mutations
and determine their independent associations with HLA alleles present (8, 10, 11). Viral
sequence mutations showing significant independent associations with HLA-C were then
filtered for predicted epitopes that fit the biochemical features of the HLA-C allele involved
(12). Twenty-two mutations were identified, representing escape at 12 epitopes that
associated with 7 HLA-C alleles (table S3). Median log odds ratios were calculated for
mutations at all epitopes associated with the same HLA-C allele to determine the strength of
selection conferred by each of these 7 HLA-C alleles (table S3). A strong positive
correlation between HLA-C expression level and the strength of selection pressure conferred
on the virus by the allele was observed (r = 0.87, P = 0.005) (Fig. 2A), indicating that higher
HLA-C expression exerts greater selection on HIV. This finding is consistent with a study of
Han Chinese that identified six viral mutations associated with HLA-C alleles that occurred
more commonly in 99 patients with the rs9264942 genotype CC than in 63 patients with the
TT genotype (13).
We analyzed cytotoxic T lymphocyte (CTL) responses to overlapping peptides spanning the
entire HIV clade C proteome, that were measured by enzyme-linked immunosorbent spot
assay in 1010 HIV subtype C–infected South African subjects (14, 15). HLA-associated
CTL responses were determined by testing the log OR of observing a response to each
peptide in the presence versus absence of every HLA class I allele, using a decision tree with
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Fisher’s exact test to discriminate associations due to linked HLA alleles (8). CTL responses
restricted by all of the 14 two-digit HLA-C alleles present in our population were observed,
comprising 71 distinct associations between a given peptide and a given HLA-C allele (table
S4). Median log ORs were calculated for responses to all peptides associating with the same
HLA-C allele. A strong correlation between the level of HLA-C allele expression and
average strength of association with CTL response to HIV was observed (r = 0.73, P =
0.002) (Fig. 2B), such that HIV peptides presented by higher expressed HLA-C alleles were
more likely to elicit CTL responses than peptides presented by low expression HLA-C
allotypes.
Of the total 60 peptides associated with HLA-C–restricted CTL responses, 8 peptides
associated with responses restricted by two different HLA-C allotypes and 4 peptides
associated with responses restricted by three different HLA-C allotypes. This permits a total
of 20 separate comparisons of the strength of response to a single peptide between two
HLA-C allotypes that differ in their level of expression (table S5). A significant correlation
was observed between the difference in HLA-C expression level for allotype pairs and the
difference in strength of association with CTL response to the same peptide when restricted
by these two allotypes (r = 0.50, P = 0.01) (Fig. 2C). That is, the likelihood of initiating a
CTL response to a given peptide correlated positively with a greater increase in expression
between the two alleles compared. These results suggest that the protective mechanism
conferred by increased HLA-C expression level occurs in part through an enhanced CTL-
mediated immune response.
The effect of HLA-C expression level in HIV disease raises the possibility of its
involvement in the risk of other human diseases. We tested this possibility in case-control
cohorts of two inflammatory bowel diseases (IBD): Crohn’s disease (CD) and ulcerative
colitis (UC). HLA-C expression as a continuous variable was considered in stepwise
selection models along with all HLA class I and II alleles with phenotypic frequencies of ≥
2%. We include class II alleles because they show the most consistent allelic effects and the
strongest MHC signal in GWAS of IBD (16–18). HLA-C expression level showed the
second most significant effect in CD (P = 3 × 10−7, OR = 1.35 for an increase of 100 MFI
units) after the well-established risk allele DRB1*01:03 (19) (table S6). HLA-C expression
level showed no effect in UC, although previously defined risk factors, such as HLA-
DRB1*01:03, were observed (16) (P = 1 × 10−12, OR = 2.03) (table S6). A greater role of
Th1 response in CD relative to UC may be related to the influence of HLA-C expression
level in risk of CD but not UC (20).
It is a novel facet of human genetic variation that HLA class I alleles vary in their expression
level between normal individuals to an extent that modulates the efficacy of an immune
response. The importance of HLA expression level is well appreciated, however, because
one of the most striking cellular changes in the inflammatory response is interferon-γ
mediated up-regulation of HLA expression (21). As few as three peptide-MHC complexes
can suffice for CTL killing in vitro (22), with increasing density improving efficiency of
cytotoxicity and modulating the response to include secretion of inflammatory cytokines
(23). Given the vast range of peptides bound by HLA class I allotypes, many individual
peptides are likely present below the threshold required for CTL activation or at a level
where increasing their density would influence the response (24). Thus, differences in
expression of even twofold, which have been shown to improve the efficacy of CTL
responses in vivo (25), could result in more beneficial control of HIV by more highly
expressed HLA-C allotypes.
Unlike its protection in HIV infection, high expression increases the risk of CD. Contrasting
effects of HLA-C expression level across human diseases may have contributed to the
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evolutionary history of the HLA-C locus, where expansion of higher expression HLA-C
allotypes has occurred over the past 4 to 5 million years since their genesis, while
maintaining lower expression allotypes (26). Thus, the complexity of HLA effects in disease
pathogenesis go beyond peptide specificity to include the strength of immune responses as
dictated by levels of HLA expression.
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Fig. 1. The distribution in expression levels of HLA-C allotypes present in African Americans
Peripheral blood CD3+ cells from 200 healthy donors were analyzed by flow cytometry for
HLA-C expression level using the monoclonal antibody DT9. MFI of HLA-C staining is
plotted twice for each donor (i.e., once for each HLA-C allele present), with HLA-C
homozygous individuals marked in red. Expression level correlates significantly with HLA-
C allotypes in analysis of variance (P = 5 × 10−21).
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Fig. 2. HLA-C expression level correlates with frequency of viral escape mutation and HIV-
specific CTL responses
(A) Analysis of viral sequences from 1888 Clade B–infected individuals revealed 12
epitopes containing viral mutations that were associated independently with an HLA-C
allele. Median ln(OR) for associations with each of the seven different HLA-C alleles
involved correlated positively with the expression level of these alleles. (B) Clade C–
infected Africans (n = 1010) were screened for CTL responses to overlapping peptides
spanning the HIV proteome, and median log OR of all responses independently associated
with each HLA-C allele are plotted. The number of peptide responses associated with each
HLA-C allele is labeled next to each point (total number of CTL responses is 71). At least
one HLA-C–restricted CTL response was detected in 71% of individuals in the population.
(C) Differences in the odds of detecting a response to the same peptide when restricted by
different HLA-C alleles correlate with the difference in expression level of these allelic
pairs. Pearson coefficients are reported for each correlation.
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Table 2
HLA-C expression level affects progression to early AIDS outcomes
HLA-C expression level as a continuous variable and all HLA class I alleles with phenotypic frequency ≥2%
were tested by stepwise selection in a Cox model, using 1069 ART-naïve patients with known times for
progression from seroconversion to CD4 < 200. Subjects comprised 783 European and 286 African
Americans, with ethnicity used as a covariate. This was justified because stratification by ethnicity indicated a
uniform strength of effects on progression across European and African Americans (table S2), which was also
apparent in the larger longitudinal VL cohorts (Table 1). Independently significant covariates are reported
with significance (P), HR, and 95% CI.
Covariate P HR 95% CI
HLA-C expression 1 × 10−6 0.67 0.55 0.74
B*57:01 2 × 10−5 0.30 0.17 0.52
C*06:02 7 × 10−4 1.75 1.26 2.41
A*26:01 2 × 10−3 0.43 0.25 0.73
B*35:03 2 × 10−3 2.11 1.3 3.41
A*11:01 3 × 10−3 0.62 0.45 0.85
A*74 4 × 10−3 0.26 0.11 0.65
A*32:01 4 × 10−3 0.53 0.34 0.82
A*31:01 3 × 10−2 0.56 0.33 0.95
B*15:01 4 × 10−2 0.72 0.52 0.99
C*04:01 4 × 10−2 1.30 1.01 1.69
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